MCENANY PATRICK J 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Nov 21, 2024
Insider Transaction Report
Form 4
MCENANY PATRICK J
DirectorPresident and CEO10% Owner
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2024-11-19$3.54/sh+98,345$348,141→ 4,576,514 total - Sale
Common stock, par value $0.001 per share
2024-11-19$21.19/sh−98,345$2,083,734→ 4,478,169 total - Sale
Common stock, par value $0.001 per share
2024-11-20$21.29/sh−72,500$1,543,525→ 4,478,169 total - Exercise/Conversion
Options to purchase common stock
2024-11-20−72,500→ 1,792,745 totalExercise: $3.54Exp: 2025-05-29→ Common Stock (72,500 underlying) - Exercise/Conversion
Common stock, par value $0.001 per share
2024-11-20$3.54/sh+72,500$256,650→ 4,550,669 total - Exercise/Conversion
Options to purchase common stock
2024-11-19−98,345→ 1,865,245 totalExercise: $3.54Exp: 2025-05-29→ Common Stock (98,345 underlying)
Footnotes (4)
- [F1]Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
- [F2]Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.11 to $21.31 per share.
- [F3]Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.05 to $21.455 per share.
- [F4]Options vested in three equal tranches on May 29, 2019, 2020 and 2021.